Governance of access pharma company ranking 2024

This statistic depicts the pharmaceutical company ranking based on general access to medicine management in developing countries as of 2024, according to the Access to Medicine Index. In that year, the company with the highest score in this category was Novartis, with a total indicator score of 4.44.

Pharmaceutical company ranking based on governance of access in developing countries as of 2024

Characteristic	Indicator score from 1 (lowest) to 5 (highest)
Novartis AG	4.44
Sanofi	4.44
GSK plc	4.36
AstraZeneca plc	4.32
Bayer AG	4.32
Johnson & Johnson	4.24
Takeda Pharamceutical Co.	4.16
Novo Nordisk A/S	4.12
Astellas Pharma Inc.	4.12
Pfizer Inc.	4.04
Merck KGaA	3.92
Boehringer-Ingelheim GmbH	3.8
Roche Holding Ltd.	3.68
Eisai Co. Ltd.	3.52
Bristol-Myers Squibb Co.	3.44
Daiichi Sankyo Co. Ltd.	3.36
Eli Lilly & Co.	3.28
Merck & Co. Inc.	3.16
Gilead Sciences	2.72
AbbVie Inc.	2.52

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

November 2024

More information

Region

Worldwide

Survey time period

As of November 2024

Supplementary notes

The Access to Medicine Index is an independent initiative that ranks the world’s 20 largest companies according to their efforts to make their products more available, affordable and accessible in developing countries, highlighting policy and practice that either facilitate or hinder access to medicine.
The Index uses a framework that evaluates company activities in seven areas of activity, or technical areas, considered to be key to enhancing access to medicine in developing countries, and across four important aspects of action, or strategic pillars.
A score of zero means lowest and five signifies highest indicator score among the company set.

Citation formats